{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:30:17Z","timestamp":1764325817424,"version":"3.46.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23jm0110018h0006"],"award-info":[{"award-number":["23jm0110018h0006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004532","name":"Japan International Cooperation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004532","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vietnam has been experiencing the transition from donor-based to social insurance-based antiretroviral therapy (ART), the COVID-19 pandemic, and expansion of dolutegravir (DTG) use. We assessed virological outcomes, care retention, and effectiveness and tolerability of switching to DTG-containing regimen among people living with HIV (PLHIV) during these changes. PLHIV with suppressed HIV viral load (HIV-VL) who were receiving ART at 11 facilities in North Vietnam were enrolled in a prospective cohort from December 2019 through September 2021 and followed up until March 2023. This cohort of 2,233 PLHIV on ART maintained viral suppression rates (HIV-VL\u2009&lt;\u200950 copies\/mL) of &gt;\u200990% and care retention rates of &gt;\u200987% throughout the study period. Incidence of viremia (HIV-VL\u2009\u2265\u2009200 copies\/mL) was 3.2\/100 person-years during follow-up. Only 32 (1.4%) PLHIV had any drug resistance mutations; no DTG-associated mutation was observed. Of 1,891 who switched to DTG-containing regimens, 292 (15.4%) discontinued DTG, most commonly owing to DTG stockout (80.8%). Average weight gain was greater in the first measurement after switching than in subsequent measurements. In conclusion, successful maintenance of virologic outcomes of ART and high treatment retention were observed amid various social and clinical changes in Vietnam. These real-world data support the national rollout of DTG.<\/jats:p>","DOI":"10.1038\/s41598-025-26866-5","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:25:54Z","timestamp":1764325554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virological outcomes and treatment retention in North Vietnam amidst transition to social insurance-based HIV services and dolutegravir-based regimens"],"prefix":"10.1038","volume":"15","author":[{"given":"Shoko","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moeko","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh Khanh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunefusa","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoai Dung Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truong Manh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giang","family":"Van Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinh","family":"Van Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thach Ngoc","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26866_CR1","unstructured":"AIDS Data Hub. Viet Nam Country Snapshot.\u00a0Accessed 11 Oct 2023.\u00a0https:\/\/www.aidsdatahub.org\/sites\/default\/files\/resource\/vnm-snapshot-2023_1.pdfhttps:\/\/www.aidsdatahub.org\/sites\/default\/files\/resource\/vnm-snapshot-2023_1.pdf (2023)."},{"key":"26866_CR2","unstructured":"World Health Organization. HIV Drug Resistance Report. Accessed 11 Oct 2023.\u00a0https:\/\/iris.who.int\/bitstream\/handle\/10665\/349340\/9789240038608-eng.pdf\u00a0(2021)."},{"key":"26866_CR3","unstructured":"The Joint United Nations Programme on HIV\/AIDS. AIDS TARGETS.\u00a0Accessed 11 Oct 2023. https:\/\/aidstargets2025.unaids.org\/\u00a0(2025)."},{"key":"26866_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/23288604.2018.1440346","volume":"4","author":"N Todini","year":"2018","unstructured":"Todini, N., Hammett, T. M. & Fryatt, R. Integrating HIV\/AIDS in vietnam\u2019s social health insurance scheme: experience and lessons from the health finance and governance Project, 2014\u20132017. Health Syst. Reform. 4, 114\u2013124. https:\/\/doi.org\/10.1080\/23288604.2018.1440346 (2018).","journal-title":"Health Syst. Reform."},{"key":"26866_CR5","doi-asserted-by":"publisher","first-page":"117863292098884","DOI":"10.1177\/1178632920988843","volume":"14","author":"LTH Vu","year":"2021","unstructured":"Vu, L. T. H. et al. Moving to social health insurance financing and payment for HIV\/AIDS treatment in Vietnam. Health Serv. Insights. 14, 1178632920988843. https:\/\/doi.org\/10.1177\/1178632920988843 (2021).","journal-title":"Health Serv. Insights"},{"key":"26866_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1057\/s41271-023-00411-y","volume":"44","author":"TT Vu","year":"2023","unstructured":"Vu, T. T. & Haley, S. J. Universal health insurance program for people living with HIV in vietnam: an ambitious approach. J. Public Health Policy. 44, 300\u2013309. https:\/\/doi.org\/10.1057\/s41271-023-00411-y (2023).","journal-title":"J. Public Health Policy"},{"key":"26866_CR7","unstructured":"Vietnam Authority of AIDS Control. Vietnam-10 years of securing finance for HIV\/AIDS prevention and control programs. Accessed 11 Oct 2023.\u00a0https:\/\/vaac.gov.vn\/viet-nam-10-nam-chang-duong-dam-bao-tai-chinh-cho-chuong-trinh-phong-chong-hiv-aids-2012-2022.html\u00a0(2022)"},{"key":"26866_CR8","unstructured":"The United States President\u2019s Emergency Plan for AIDS Relief. Vietnam country operational plan (COP\/ROP) 2021 - Strategic direction summary. Accessed 11 Oct 2023.\u00a0https:\/\/www.state.gov\/wp-content\/uploads\/2021\/09\/Vietnam_SDS-_Final-Public_Aug-11-2021.pdf\u00a0(2021)."},{"key":"26866_CR9","unstructured":"Our World in Data. Vietnam: Coronavirus Pandemic Country Profile. Oct Accessed 11. https:\/\/ourworldindata.org\/coronavirus\/country\/vietnam (2023)."},{"key":"26866_CR10","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/s2352-3018(20)30305-2","volume":"8","author":"K Bhaskaran","year":"2021","unstructured":"Bhaskaran, K. et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked National death registrations within the opensafely platform. Lancet HIV. 8, e24\u2013e32. https:\/\/doi.org\/10.1016\/s2352-3018(20)30305-2 (2021).","journal-title":"Lancet HIV"},{"key":"26866_CR11","doi-asserted-by":"publisher","unstructured":"Tesoriero, J. M. et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA network open 4, e2037069, https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37069 (2021).","DOI":"10.1001\/jamanetworkopen.2020.37069"},{"key":"26866_CR12","doi-asserted-by":"publisher","first-page":"e0270831","DOI":"10.1371\/journal.pone.0270831","volume":"17","author":"CC Hung","year":"2022","unstructured":"Hung, C. C. et al. Impact of COVID-19 on the HIV care continuum in asia: insights from people living with HIV, key populations, and HIV healthcare providers. PloS One. 17, e0270831. https:\/\/doi.org\/10.1371\/journal.pone.0270831 (2022).","journal-title":"PloS One"},{"key":"26866_CR13","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1002\/hpm.3508","volume":"37","author":"H Nguyen Thu","year":"2022","unstructured":"Nguyen Thu, H., Nguyen Quynh, A., Khuat Hai, O., Le Thi Thanh, H. & Nguyen Thanh, H. Impact of the COVID-19 pandemic on provision of HIV\/AIDS services for key populations. Int. J. Health Plann. Manag. 37, 2852\u20132868. https:\/\/doi.org\/10.1002\/hpm.3508 (2022).","journal-title":"Int. J. Health Plann. Manag."},{"key":"26866_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.35772\/ghm.2021.01103","volume":"3","author":"S Oka","year":"2021","unstructured":"Oka, S. HIV testing in COVID-19 pandemic and beyond in Japan. Global Health Med. 3, 356\u2013357. https:\/\/doi.org\/10.35772\/ghm.2021.01103 (2021).","journal-title":"Global Health Med."},{"key":"26866_CR15","doi-asserted-by":"publisher","unstructured":"SeyedAlinaghi, S. et al. The impacts of COVID-19 pandemic on service delivery and treatment outcomes in people living with HIV: a systematic review. AIDS Res. Therapy. 20 (4). https:\/\/doi.org\/10.1186\/s12981-022-00496-7 (2023).","DOI":"10.1186\/s12981-022-00496-7"},{"key":"26866_CR16","doi-asserted-by":"crossref","unstructured":"World Health Organization. Impact of COVID-19 on the global supply chain of antiretroviral drugs: a rapid survey of Indian manufacturers. Accessed 11 Oct 2023. https:\/\/iris.who.int\/bitstream\/handle\/10665\/334196\/seajph2020v9n2p126-eng.pdf?sequence=1&isAllowed=y\u00a0(2020).","DOI":"10.4103\/2224-3151.294306"},{"key":"26866_CR17","doi-asserted-by":"publisher","first-page":"e26060","DOI":"10.1002\/jia2.26060","volume":"26","author":"C Hong","year":"2023","unstructured":"Hong, C., Queiroz, A. & Hoskin, J. The impact of the COVID-19 pandemic on mental health, associated factors and coping strategies in people living with HIV: a scoping review. J. Int. AIDS. Soc. 26, e26060. https:\/\/doi.org\/10.1002\/jia2.26060 (2023).","journal-title":"J. Int. AIDS. Soc."},{"key":"26866_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton, N. I. et al. Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV. N. Engl. J. Med. 385, 330\u2013341. https:\/\/doi.org\/10.1056\/NEJMoa2101609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"26866_CR19","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley, S. L. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl. J. Med. 369, 1807\u20131818. https:\/\/doi.org\/10.1056\/NEJMoa1215541 (2013).","journal-title":"N Engl. J. Med."},{"key":"26866_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","volume":"52","author":"ML Cottrell","year":"2013","unstructured":"Cottrell, M. L., Hadzic, T. & Kashuba, A. D. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin. Pharmacokinet. 52, 981\u2013994. https:\/\/doi.org\/10.1007\/s40262-013-0093-2 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"26866_CR21","first-page":"56","volume":"17","author":"JM Llibre","year":"2015","unstructured":"Llibre, J. M. et al. Genetic barrier to resistance for dolutegravir. AIDS Rev. 17, 56\u201364 (2015).","journal-title":"AIDS Rev."},{"key":"26866_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41598-023-51144-7","volume":"14","author":"A Fimbo","year":"2024","unstructured":"Fimbo, A. et al. Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in Mainland Tanzania. Sci. Rep. 14, 615. https:\/\/doi.org\/10.1038\/s41598-023-51144-7 (2024).","journal-title":"Sci. Rep."},{"key":"26866_CR23","doi-asserted-by":"publisher","first-page":"e25899","DOI":"10.1002\/jia2.25899","volume":"25","author":"AL Esber","year":"2022","unstructured":"Esber, A. L. et al. Weight gain during the dolutegravir transition in the African cohort study. J. Int. AIDS. Soc. 25, e25899. https:\/\/doi.org\/10.1002\/jia2.25899 (2022).","journal-title":"J. Int. AIDS. Soc."},{"key":"26866_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/qai.0000000000001525","volume":"76","author":"J Norwood","year":"2017","unstructured":"Norwood, J. et al. Brief report: weight gain in persons with HIV switched from Efavirenz-Based to integrase strand transfer Inhibitor-Based regimens. J. Acquir. Immune Defic. Syndr. 76, 527\u2013531. https:\/\/doi.org\/10.1097\/qai.0000000000001525 (2017).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"26866_CR25","unstructured":"World Health Organization. Update Of Recommendations on First- and Second-line Antiretroviral Regimen.\u00a0Accessed 11 Oct 2023.\u00a0https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-19.15\u00a0(2019)."},{"key":"26866_CR26","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed. Accessed 11 Oct 2023.\u00a0https:\/\/www.who.int\/publications\/i\/item\/9789241549684\u00a0(2016)."},{"key":"26866_CR27","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed 13 Mar 2024.\u00a0https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf (2024)."},{"key":"26866_CR28","unstructured":"British, H. I. V. & Association BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update).\u00a0https:\/\/www.bhiva.org\/file\/RVYKzFwyxpgiI\/treatment-guidelines-2016-interim-update.pdf\u00a0(2016)."},{"key":"26866_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.35772\/ghm.2023.01112","volume":"6","author":"GV Tran","year":"2024","unstructured":"Tran, G. V. et al. Prevalence of transmitted drug resistance and phylogenetic analysis of HIV-1 among antiretroviral therapy-na\u00efve patients in Northern Vietnam from 2019 to 2022. Global Health Med. 6, 117\u2013123. https:\/\/doi.org\/10.35772\/ghm.2023.01112 (2024).","journal-title":"Global Health Med."},{"key":"26866_CR30","doi-asserted-by":"publisher","unstructured":"Aoko, A. et al. Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya. EClinicalMedicine 63, 102166, https:\/\/doi.org\/10.1016\/j.eclinm.2023.102166 (2023).","DOI":"10.1016\/j.eclinm.2023.102166"},{"key":"26866_CR31","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1097\/qad.0000000000003672","volume":"37","author":"HM Chun","year":"2023","unstructured":"Chun, H. M. et al. Reaching HIV epidemic control in Nigeria using a lower HIV viral load suppression cut-off. AIDS (London England). 37, 2081\u20132085. https:\/\/doi.org\/10.1097\/qad.0000000000003672 (2023).","journal-title":"AIDS (London England)"},{"key":"26866_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4212\/cjhp.3234","volume":"75","author":"AR McClean","year":"2022","unstructured":"McClean, A. R. et al. Trends in use of combination antiretroviral therapy and treatment response from 2000 to 2016 in the Canadian observational cohort (CANOC): A longitudinal cohort study. Can. J. Hosp. Pharm. 75, 309\u2013316. https:\/\/doi.org\/10.4212\/cjhp.3234 (2022).","journal-title":"Can. J. Hosp. Pharm."},{"key":"26866_CR33","doi-asserted-by":"publisher","unstructured":"Tanuma, J. et al. Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam. J. Int. AIDS Soc. 20,\u00a0https:\/\/doi.org\/10.1002\/jia2.25030 (2017).","DOI":"10.1002\/jia2.25030"},{"key":"26866_CR34","doi-asserted-by":"publisher","first-page":"e0139594","DOI":"10.1371\/journal.pone.0139594","volume":"10","author":"S Matsumoto","year":"2015","unstructured":"Matsumoto, S. et al. High treatment retention rate in HIV-Infected patients receiving antiretroviral therapy at two large HIV clinics in Hanoi, Vietnam. PloS One. 10, e0139594. https:\/\/doi.org\/10.1371\/journal.pone.0139594 (2015).","journal-title":"PloS One"},{"key":"26866_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/qad.0000000000003491","volume":"37","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. The impact of COVID-19 pandemic on the dynamic HIV care engagement among people with HIV: real-world evidence. AIDS (London England). 37, 951\u2013956. https:\/\/doi.org\/10.1097\/qad.0000000000003491 (2023).","journal-title":"AIDS (London England)"},{"key":"26866_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s10461-021-03464-w","volume":"26","author":"S Matsumoto","year":"2022","unstructured":"Matsumoto, S. et al. Evaluation of SARS-CoV-2 antibodies and the impact of COVID-19 on the HIV care Continuum, economic Security, risky health Behaviors, and mental health among HIV-Infected individuals in Vietnam. AIDS Behav. 26, 1095\u20131109. https:\/\/doi.org\/10.1007\/s10461-021-03464-w (2022).","journal-title":"AIDS Behav."},{"key":"26866_CR37","unstructured":"World Health Organization. HIV Drug Resistance Report. Accessed 11 Oct 2023. https:\/\/iris.who.int\/bitstream\/handle\/10665\/255896\/9789241512831-eng.pdf?sequence=1\u00a0(2017)."},{"key":"26866_CR38","doi-asserted-by":"publisher","first-page":"e25857","DOI":"10.1002\/jia2.25857","volume":"25","author":"VQ Dat","year":"2022","unstructured":"Dat, V. Q. et al. The prevalence of pre-treatment and acquired HIV drug resistance in vietnam: a nationally representative survey, 2017\u20132018. J. Int. AIDS. Soc. 25, e25857. https:\/\/doi.org\/10.1002\/jia2.25857 (2022).","journal-title":"J. Int. AIDS. Soc."},{"key":"26866_CR39","doi-asserted-by":"publisher","unstructured":"Allahna, E. et al. Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study. Journal of acquired immune deficiency syndromes\u00a0(1999).\u00a091, 285\u2013289. https:\/\/doi.org\/10.1097\/qai.0000000000003065 (2022).","DOI":"10.1097\/qai.0000000000003065"},{"key":"26866_CR40","doi-asserted-by":"publisher","first-page":"e25227","DOI":"10.1002\/jia2.25227","volume":"22","author":"A Mondi","year":"2019","unstructured":"Mondi, A. et al. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J. Int. AIDS. Soc. 22, e25227. https:\/\/doi.org\/10.1002\/jia2.25227 (2019).","journal-title":"J. Int. AIDS. Soc."},{"key":"26866_CR41","doi-asserted-by":"publisher","unstructured":"Semengue, E. N. J. et al. Dolutegravir-Based regimen ensures high virological success despite prior exposure to Efavirenz-Based First-LINE ART in cameroon: an evidence of a successful transition model. Viruses 15,\u00a0https:\/\/doi.org\/10.3390\/v15010018 (2022).","DOI":"10.3390\/v15010018"},{"key":"26866_CR42","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1016\/s2352-3018(23)00228-x","volume":"10","author":"T Loosli","year":"2023","unstructured":"Loosli, T. et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV. 10, e733\u2013e741. https:\/\/doi.org\/10.1016\/s2352-3018(23)00228-x (2023).","journal-title":"Lancet HIV"},{"key":"26866_CR43","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/s2352-3018(17)30152-2","volume":"4","author":"I Wijting","year":"2017","unstructured":"Wijting, I. et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 4, e547\u2013e554. https:\/\/doi.org\/10.1016\/s2352-3018(17)30152-2 (2017).","journal-title":"Lancet HIV"},{"key":"26866_CR44","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1097\/qad.0000000000001279","volume":"30","author":"MG de Boer","year":"2016","unstructured":"de Boer, M. G. et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS (London England). 30, 2831\u20132834. https:\/\/doi.org\/10.1097\/qad.0000000000001279 (2016).","journal-title":"AIDS (London England)"},{"key":"26866_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann, C. et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 18, 56\u201363. https:\/\/doi.org\/10.1111\/hiv.12468 (2017).","journal-title":"HIV Med."},{"key":"26866_CR46","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1093\/jac\/dkac306","volume":"77","author":"WM Han","year":"2022","unstructured":"Han, W. M., Kerr, S. J., Avihingsanon, A. & Boettiger, D. C. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV. J. Antimicrob. Chemother. 77, 3242\u20133247. https:\/\/doi.org\/10.1093\/jac\/dkac306 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"26866_CR47","doi-asserted-by":"publisher","first-page":"e25324","DOI":"10.1002\/jia2.25324","volume":"22","author":"OQ Goh","year":"2019","unstructured":"Goh, O. Q. et al. Switch to dolutegravir is well tolerated in Thais with HIV infection. J. Int. AIDS. Soc. 22, e25324. https:\/\/doi.org\/10.1002\/jia2.25324 (2019).","journal-title":"J. Int. AIDS. Soc."},{"key":"26866_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/qco.0000000000000616","volume":"33","author":"AR Eckard","year":"2020","unstructured":"Eckard, A. R. & McComsey, G. A. Weight gain and integrase inhibitors. Curr. Opin. Infect. Dis. 33, 10\u201319. https:\/\/doi.org\/10.1097\/qco.0000000000000616 (2020).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"26866_CR49","first-page":"199","volume":"16","author":"F Guti\u00e9rrez","year":"2014","unstructured":"Guti\u00e9rrez, F., Fulladosa, X., Barril, G. & Domingo, P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 16, 199\u2013212 (2014).","journal-title":"AIDS Rev."},{"key":"26866_CR50","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jiac.2018.03.002","volume":"24","author":"D Mizushima","year":"2018","unstructured":"Mizushima, D. et al. Tenofovir disoproxil fumarate co-administered with lopinavir\/ritonavir is strongly associated with tubular damage and chronic kidney disease. J. Infect. Chemotherapy: Official J. Japan Soc. Chemother. 24, 549\u2013554. https:\/\/doi.org\/10.1016\/j.jiac.2018.03.002 (2018).","journal-title":"J. Infect. Chemotherapy: Official J. Japan Soc. Chemother."},{"key":"26866_CR51","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jiac.2014.08.015","volume":"20","author":"D Mizushima","year":"2014","unstructured":"Mizushima, D. et al. Low body weight and Tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. J. Infect. Chemotherapy: Official J. Japan Soc. Chemother. 20, 784\u2013788. https:\/\/doi.org\/10.1016\/j.jiac.2014.08.015 (2014).","journal-title":"J. Infect. Chemotherapy: Official J. Japan Soc. Chemother."},{"key":"26866_CR52","unstructured":"Vietnam Authority of AIDS Control. Guidelines for HIV\/AIDS treatment and care (No 5968\/QD-BYT). (2021)."},{"key":"26866_CR53","unstructured":"Kitaki, H. Technical Efficiency of Public and Private Hospitals in Vietnam: Do Market-Oriented Policies Matter? No 163. (Working Papers from JICA Research Institute, 2018)."},{"key":"26866_CR54","doi-asserted-by":"publisher","first-page":"14225","DOI":"10.1038\/s41598-024-64898-5","volume":"14","author":"NT Trang","year":"2024","unstructured":"Trang, N. T. et al. Detection of co-infection and recombination cases with Omicron and local delta variants of SARS-CoV-2 in Vietnam. Sci. Rep. 14, 14225. https:\/\/doi.org\/10.1038\/s41598-024-64898-5 (2024).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26866-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26866-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26866-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:26:03Z","timestamp":1764325563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26866-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26866"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26866-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42657"}}